BioSenic S.A. (0R55.L)

EUR 0.01

(-14.29%)

Net Debt Summary of BioSenic S.A.

  • BioSenic S.A.'s latest annual net debt in 2023 was 28.04 Million EUR , up 47.69% from previous year.
  • BioSenic S.A.'s latest quarterly net debt in 2024 Q2 was 24.86 Million EUR , up 4.47% from previous quarter.
  • BioSenic S.A. reported annual net debt of 18.98 Million EUR in 2022, up 68.21% from previous year.
  • BioSenic S.A. reported annual net debt of 11.28 Million EUR in 2021, up 7475.84% from previous year.
  • BioSenic S.A. reported quarterly net debt of 24.86 Million EUR for 2024 Q1, down -11.33% from previous quarter.
  • BioSenic S.A. reported quarterly net debt of 28.04 Million EUR for 2023 Q3, up 14.39% from previous quarter.

Annual Net Debt Chart of BioSenic S.A. (2023 - 2011)

Historical Annual Net Debt of BioSenic S.A. (2023 - 2011)

Year Net Debt Net Debt Growth
2023 28.04 Million EUR 47.69%
2022 18.98 Million EUR 68.21%
2021 11.28 Million EUR 7475.84%
2020 149 Thousand EUR -97.07%
2019 5.08 Million EUR 8.61%
2018 4.67 Million EUR 37.95%
2017 3.39 Million EUR 142.97%
2016 -7.89 Million EUR 62.74%
2015 -21.17 Million EUR -387.47%
2014 7.36 Million EUR 136.05%
2013 3.12 Million EUR 706.02%
2012 -515 Thousand EUR 77.77%
2011 -2.31 Million EUR 0.0%

Peer Net Debt Comparison of BioSenic S.A.

Name Net Debt Net Debt Difference
Boiron SA -60.34 Million EUR 146.475%
Laboratorios Farmaceuticos Rovi, S.A. 21.31 Million EUR -31.582%
Vetoquinol SA -129.83 Million EUR 121.6%
Valneva SE 82.73 Million EUR 66.104%
AB Science S.A. 13.03 Million EUR -115.144%
Nanobiotix S.A. -29.8 Million EUR 194.107%
PHAXIAM Therapeutics S.A. -275 Thousand EUR 10297.818%
Vivoryon Therapeutics N.V. -18.52 Million EUR 251.393%
ABIVAX Société Anonyme -196.47 Million EUR 114.273%
Formycon AG 2.45 Million EUR -1044.186%